Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06341829 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Visuospatial and Affective Abilities in Parkinson Disease

StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Not Yet Recruiting to Enrolling by Invitationv3 Show 6 more changesShow less
    • Enrollment target: 63 to 126
    • Study sites: 0 to 1
    • Primary completion date changed from estimate of Apr 18, 2024 to May 1, 2024
    • Start date changed from estimate of Apr 17, 2024 to Apr 30, 2024
    • Interventions: Prismatic adaptation (Other) to Prismatic adaptation (Other), Schirmer test (Diagnostic Test)
    • Secondary endpoints: 1 to 2
  2. Primary completion date: Apr 6, 2024 to Apr 18, 2024
    • Start date: Apr 4, 2024 to Apr 17, 2024
    • Secondary endpoints: details revised at 1 of 1 entry
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of the study is to investigate whether prismatic adaptation (PA) and virtual prismatic adaptation (VPA), a non-invasive neuromodulation technique, that involves the use of lenses that deviate the visual field, can modulate alexithyima and performance in visuospatial tasks in patients with Parkinson disease. Furthermore, brain activity during the prismatic adaptation and post-adaptation phases will be recorded using functional near-infrared spectroscopy (fNIRS) and high-density electroencephalography (HD-EEG). Based on these premises, the present project aims to investigate the deficits of the affective, motor and visuospatial abilities in Parkinson's patients and the modulation of disorders through prismatic adaptation (PA) and virtual prism adaptation (VPA). Finally, we would like to evaluate production of the tear film and correlate their quantity with the severity of PD as it could be proposed as a new, non-invasive biomarker.
Trial Details
NCT Number NCT06341829
Lead Sponsor IRCCS Centro Neurolesi Bonino Pulejo
Conditions
(from sponsor)		 Parkinson Disease, Alexithymia, Visuospatial/Perceptual Abilities
Related terms Affective Symptoms, Parkinson Disease
Enrollment 126 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov